An observational study in Urinary Diversion, Urinary Bladder Carcinoma and Neurogenic Bladder, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Hospices Civils de Lyon · Observational
Among 160 studies in Urinary Bladder Neoplasms with a site in France — 40 open to participants now, 62 under way, 15 of them phase 3. Urinary Bladder Neoplasms · France.
Among the 160 studies in Urinary Bladder Neoplasms with a site in France, this one is the 25th largest by planned enrollment of the 29 observational ones that give a count, is one of 8 that started in 2026, is one of 29 observational ones, reaches primary completion later than 23 of the 61 other live ones, and was the 160th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →40 of the 160 studies in Urinary Bladder Neoplasms with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 13 more countries
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 14 more countries
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in France, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 61 · Phase 3 30 · Phase 4 1
First in 1997; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 200 across 412 observational studies indexed under Urinary Bladder Neoplasms.
Median enrollment 169 across the 129 interventional studies, 293 across the 29 observational. Of the 94 that completed or were terminated, 40 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 160 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,867 studies on the registry; 448 are open to participants now.
Hospices Civils de Lyon has 2 studies filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
21 of the studies in Urinary Bladder Neoplasms with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT04241185Phase 3Merck Sharp & Dohme LLCEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | 2027-01-31 |
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
| NCT03915678Institut BergoniéAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 160 studies in Urinary Bladder Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Miami Pouch is a continent cutaneous urinary diversion using the plicated right colon and the ileocecal valve as a catheterizable continent stoma. Despite its long history, functional outcomes remain poorly reported, with no consensus on continence definition or standardized assessment tools.
This single-center cross sectional cohort study evaluates functional outcomes in patients who underwent Miami Pouch urinary diversion at Hôpital Lyon Sud (Hospices Civils de Lyon, France) between 2015 and 2025. Patients were identified through institutional medical coding (PMSI) and contacted by telephone to complete validated patient-reported outcome measures.
The primary objective is to assess stomal continence using the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF).
Hypothesis: The Miami Pouch provides acceptable long-term stomal continence with limited impact on digestive function.
Consecutive patients who underwent Miami Pouch continent cutaneous urinary diversion at the Urology Department of Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France, between 2015 and 2025. 35 patients estimation.
Patients identification through institutional surgical coding (PMSI) and contacted by phone for study participation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adult patients who underwent Miami Pouch continent cutaneous urinary diversion at the Urology Department of Hôpital Lyon Sud (HCL) between 2015 and 2025, with a minimum postoperative follow-up of 6 months
Other: Patient reported outcome measures · Other: 24-Hour Stomal Pad Test
Patients completed four validated questionnaires by telephone: the ICIQ-SF (urinary symptom frequency and impact), the SF-Qualiveen (urinary quality of life in neurogenic and non-neurogenic patients), a modified 20-item Gastrointestinal Quality of Life Index (digestive quality of life), and the Bristol Stool Scale (stool consistency)
Patients performed a self-administered 24-hour stomal pad test at home. Absorbent pads were weighed before and after placement over the stoma. Total pad weight gain (grams) over 24 hours was used as an objective measure of stomal urinary leakage.
Stomal Continence Rate
Stomal continence classified into three categories based on ICIQ-SF questionnaire : * No Leakage * Occasional Leakage * Daily Leakage. Social continence defined as No Leakage or Occasional Leakage.
Time frame: 6 months post-surgery
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.